Dexibuprofen is a specially obtained right–rotating isomer of the substance ibuprofen (isomers are substances having the same composition, but different spatial arrangement of atoms and, as a result, different properties). Only the right-rotating isomer of ibuprofen has the ability to inhibit the activity of cyclooxygenase (an enzyme involved in the development of inflammation). This leads to a more pronounced reduction in the symptoms of pain and inflammation. The structural features of dexibuprofen allow it to dissolve faster in the acidic environment of the stomach, penetrate through membrane barriers and bind better to receptors, which leads to an accelerated analgesic effect and a longer duration of action compared to the racemic ibuprofen mixture (a mixture of right-rotating and left-rotating isomers of ibuprofen).
Dexibuprofen has analgesic, anti-inflammatory and antipyretic effects.

The drug REITBUFEN is indicated for use in adults over the age of 18 for symptomatic treatment:

• mild to moderate pain, including headache, migraine, toothache, muscle pain, and joint pain;
• painful sensations during menstruation (primary dysmenorrhea);
• pain and inflammation associated with osteoarthritis (a chronic joint disease in which there is a gradual destruction of cartilage, changes in the underlying bone, inflammation of the synovial membrane, muscles, ligaments of joints);

Most cases of dexibuprofen overdose are asymptomatic. As a rule, overdose symptoms appear within 4 hours. The most common symptoms of overdose are mild, including abdominal pain, nausea, vomiting, lethargy, drowsiness, headache, frequent involuntary eye twitching (nystagmus), tinnitus, and movement coordination disorder (ataxia).

Symptoms of moderate to severe overdose are rare; they include gastrointestinal bleeding, a decrease in blood pressure below normal (hypotension), a decrease in temperature below normal (hypothermia), a violation of the acid-base balance of the body (metabolic acidosis), seizures, impaired kidney function, coma, severe respiratory failure in adults (respiratory distress syndrome in adults) and transient episodes of respiratory arrest (apnea) (in very young children after ingestion of a large amount of the drug).

Like all medications, the drug REITBUFEN can cause undesirable reactions, but they do not occur in everyone. The likelihood of adverse reactions from the gastrointestinal tract is reduced if dexibuprofen is taken in low doses or for a short time.
Stop taking REITBUFEN and seek immediate medical attention if any of the following signs of serious adverse reactions occur:
• gastrointestinal ulcers, sometimes with bleeding and perforation (they can occur frequently − no more than 1 in 10 people), the signs of which may be black, tar-like stools (melena), vomiting with blood, pain in the upper abdomen, nausea, weakness, dizziness, tinnitus;
• bullous reactions, including Stevens-Johnson syndrome and acute toxic epidermal necrolysis (Lyell's syndrome); erythema multiforme; drug-induced reaction with eosinophilia and systemic symptoms (DRESS syndrome); acute generalized exanthematous pustulosis (OGEP) (may occur very rarely – no more than 1 person out of 10,000 or with unknown frequency – it is impossible to estimate based on available data) – severe skin reactions with high body temperature, pain and swelling in the throat, severe itching, peeling of the skin, formation of blisters (blisters) on the skin and mucous membranes of the lips, eyes, mouth, nose, genitals, accompanied by bleeding;
• angioedema (may occur very rarely – no more than 1 in 10,000 people) – rapid swelling of the skin (lips, eyelids), subcutaneous tissue, mucous membranes or submucosa (tongue, tonsils, soft palate); • severe allergic reactions (may occur very rarely – in no more than 1 person out of 10,000), including swelling of the face, swelling of the tongue, and the inner part of the larynx with narrowing of the airways, difficulty breathing, tachycardia, and decreased blood pressure, the development of potentially life-threatening shock, and exacerbation of bronchial asthma;
• aseptic meningitis (it can occur very rarely – in no more than 1 person out of 10,000), the signs of which are severe headache, high body temperature, neck stiffness or intolerance to bright light; • myocardial infarction (may occur very rarely – in no more than 1 person out of 10,000), possible signs of which are burning chest pain with spread to the left shoulder blade, left arm, shortness of breath, weakness, sweating); • a sharp decrease in the number of cells responsible for immunity in the blood (agranulocytosis, determined by the results of a blood test) (it can occur very rarely – no more than 1 person out of 10,000). Early signs include fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe exhaustion, nosebleeds, and skin hemorrhages. In such cases, it is necessary to immediately stop treatment, avoid self-treatment with analgesics or antipyretics, and consult a doctor.

(For more information about all possible adverse reactions, see the leaflet)

Do not take the drug REITBUFEN if:
• You are allergic to dexibuprofen, NSAIDs or any other components of the drug listed in section 6 of the leaflet;
• Have you ever had the following allergic reactions after taking acetylsalicylic acid (aspirin) or other NSAIDs: bronchospasm, bronchial asthma, runny nose (rhinitis), formation of polyps in the nasal cavity, angioedema or urticaria; • You have had gastrointestinal bleeding or violations of the integrity of the gastrointestinal wall (gastrointestinal perforation) associated with previous NSAID therapy;
• you have hematopoiesis disorders, the cause of which is unknown;
• you have erosive and ulcerative diseases of the gastrointestinal tract (including peptic ulcer of the stomach and duodenum, chronic inflammatory disease of the gastrointestinal tract, characterized by damage to the intestinal wall with the development of complications (Crohn's disease), inflammatory disease of the colon, accompanied by the formation of ulcers on the mucous membrane (ulcerative colitis)), existing or recurrent peptic ulcer, current or previous bleeding (two or more separate episodes of confirmed ulcer or bleeding); • You have been diagnosed with a brain hemorrhage or other active bleeding;
• You have an increased tendency to bleeding (hemorrhagic diathesis) and other blood clotting disorders; • You have severe liver failure;
• You have severe kidney failure;
• You have severe heart failure;
• You have severe dehydration (for example, due to vomiting, frequent loose stools (diarrhea), and insufficient fluid intake); • You are pregnant (more than 20 weeks old).

Tell your doctor that you are taking, have recently taken, or may start taking any other medications (For more information about the entire list of medications, see the instructions in the leaflet)

Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
An organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro

Keep the drug out of the reach of the child so that the child cannot see it. Do not take the drug after the expiration date (shelf life) indicated on the carton after "Good before". The expiration date is the last day of the given month. Store at a temperature not exceeding 25 ° C. Store in the original packaging (pack) to protect from light.

Adverse reactions such as dizziness, fatigue, drowsiness, and visual disturbances may occur while taking the drug REITBUFEN. If you experience the above adverse reactions, refrain from driving vehicles and working with mechanisms. No special precautions are required for single or short-term use of the drug REITBUFEN.